InMed Pharmaceuticals, Inc. (OTCMKTS:IMLFF) posted that it has placed a provisional patent application in the U.S. for ‘INM-085’. It is a cannabinoid-based topical medication targeting glaucoma. This marks as a considerable progress towards attaining intellectual and commercial protection for this specific therapy.
A couple of months ago, InMed Pharmaceuticals posted about the filing of a Patent Cooperation Treaty application. This marks a key cog in attaining intellectual and commercial protection for its medication INM-750 targeting EBS.
Epidermolysis Bullosa can be explicated as a group of hereditary connective tissue disorders that have a common appearance of fragile skin that tears/blisters from trauma/friction. Even bodily systems as well as other organs can be impacted by EB.
It is a consequence of a defect of attaching between the epidermis and dermis instigated frequently by the deficiency or dysfunction of definite proteins in the skin. EB is an orphan disorder with an unmet medical need and so far with no known therapy. INM-750 will be the pilot treatment advanced for EB, directed specifically to assuage symptoms and to curb disease activity.
It is a familiar fact that cannabinoid compounds exhibit anti-inflammatory, wound healing and pain-relieving promoting properties by different mechanisms, making them good contender for use in mitigating some of the symptoms allied with EB.
Bioinformatics Database Assessment Tool of InMed estimated a dual methodology that may be advantageous to people: first, the capacity of certain CBDs to play a part in determining major illness hallmarks in people with EB; and second, the capability of some cannabinoids to regulate the expression of discrete keratins that might compensate for the dysfunctional proteins, entitled keratins, that lead EBS. EBS accounts for a big majority of folks with EB. InMed performed many in-vivo and in-vitro assays and the products of these trials form the substance of this PCT application.